Cargando…

The development of anticholinergics in the management of COPD

Anticholinergics have been used to treat obstructive respiratory disease for many years from historical preparations of the deadly nightshade genus, to the more recent developments of ipratropium, oxitropium, and tiotropium. The medical treatment of airways obstruction has focused on achieving maxim...

Descripción completa

Detalles Bibliográficos
Autor principal: Scullion, Jane E
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2692120/
https://www.ncbi.nlm.nih.gov/pubmed/18044064
_version_ 1782167933145841664
author Scullion, Jane E
author_facet Scullion, Jane E
author_sort Scullion, Jane E
collection PubMed
description Anticholinergics have been used to treat obstructive respiratory disease for many years from historical preparations of the deadly nightshade genus, to the more recent developments of ipratropium, oxitropium, and tiotropium. The medical treatment of airways obstruction has focused on achieving maximal airway function through bronchodilators. Of the two main bronchodilators, beta2-agonists are often the first treatment choice although there is evidence of equivalence and some suggestions of the superiority of anticholinergics in chronic obstructive pulmonary disease (COPD). The following review looks at the background of anticholinergics, their pharmacological properties, and the evidence for use with suggestions for their place in the treatment of COPD.
format Text
id pubmed-2692120
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-26921202009-06-16 The development of anticholinergics in the management of COPD Scullion, Jane E Int J Chron Obstruct Pulmon Dis Review Anticholinergics have been used to treat obstructive respiratory disease for many years from historical preparations of the deadly nightshade genus, to the more recent developments of ipratropium, oxitropium, and tiotropium. The medical treatment of airways obstruction has focused on achieving maximal airway function through bronchodilators. Of the two main bronchodilators, beta2-agonists are often the first treatment choice although there is evidence of equivalence and some suggestions of the superiority of anticholinergics in chronic obstructive pulmonary disease (COPD). The following review looks at the background of anticholinergics, their pharmacological properties, and the evidence for use with suggestions for their place in the treatment of COPD. Dove Medical Press 2007-03 2007-03 /pmc/articles/PMC2692120/ /pubmed/18044064 Text en © 2007 Dove Medical Press Limited. All rights reserved
spellingShingle Review
Scullion, Jane E
The development of anticholinergics in the management of COPD
title The development of anticholinergics in the management of COPD
title_full The development of anticholinergics in the management of COPD
title_fullStr The development of anticholinergics in the management of COPD
title_full_unstemmed The development of anticholinergics in the management of COPD
title_short The development of anticholinergics in the management of COPD
title_sort development of anticholinergics in the management of copd
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2692120/
https://www.ncbi.nlm.nih.gov/pubmed/18044064
work_keys_str_mv AT scullionjanee thedevelopmentofanticholinergicsinthemanagementofcopd
AT scullionjanee developmentofanticholinergicsinthemanagementofcopd